In Vitro Activities of Garenoxacin (BMS 284756) Against 108 Clinical Isolates of Gardnerella Vaginalis
Overview
Authors
Affiliations
Garenoxacin (BMS 284756) was active against 105 of 108 (97%) recent clinical Gardnerella vaginalis isolates at < or =2 micro g/ml by using the reference agar dilution method for anaerobes. Twenty-eight percent of isolates (31 of 108) were resistant to metronidazole, and 44% were resistant to doxycycline. All were susceptible to clindamycin and ampicillin-sulbactam.
Gardnerella vaginalis population dynamics in bacterial vaginosis.
Hilbert D, Schuyler J, Adelson M, Mordechai E, Sobel J, Gygax S Eur J Clin Microbiol Infect Dis. 2017; 36(7):1269-1278.
PMID: 28197729 DOI: 10.1007/s10096-017-2933-8.
Advances in the Prevention of Infection-Related Preterm Birth.
Lamont R Front Immunol. 2015; 6:566.
PMID: 26635788 PMC: 4644786. DOI: 10.3389/fimmu.2015.00566.
Schuyler J, Mordechai E, Adelson M, Gygax S, Hilbert D Genome Announc. 2015; 3(6).
PMID: 26564054 PMC: 4972788. DOI: 10.1128/genomeA.01345-15.
Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.
Mendling W, Weissenbacher E, Gerber S, Prasauskas V, Grob P Arch Gynecol Obstet. 2015; 293(3):469-84.
PMID: 26506926 PMC: 4757629. DOI: 10.1007/s00404-015-3914-8.
Draft Genome Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate.
Schuyler J, Chadwick S, Mordechai E, Adelson M, Gygax S, Hilbert D Genome Announc. 2015; 3(5).
PMID: 26337887 PMC: 4559736. DOI: 10.1128/genomeA.00992-15.